Myriad Genetics Analyst Price Targets - Benzinga

Myriad Genetics Inc

MYGNNASDAQ

Trade with Public

Trade with Public

$4.54

0.4811.82%

Ult. Agg.: Oct 5, 3:52 AM

$4.55

0.4912.07%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Myriad Genetics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Myriad Genetics (MYGN).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

4Buy

5Hold

4Sell

Consensus RatingEqual-Weight# Analysts13Avg. Consensus PT$10Upside to Avg. PT+128.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Craig-Hallum	John Wilkin	PT Raise	Buy	$4→$8
Sep 9, 2026	UBS	Lu Li	PT Cut	Neutral	$6→$4
Sep 1, 2026	Piper Sandler	David Westenberg	Downgrade	Overweight→Underweight	$5→$2
Aug 18, 2026	Stephens & Co.	Mason Carrico	PT Cut	Equal-Weight	$5→$3
Aug 3, 2026	Wells Fargo	Evan Stampler	PT Cut	Equal-Weight	$6→$3
Jul 31, 2026	TD Cowen	Kyle Boucher	PT Cut	Hold	$6→$4
May 6, 2026	TD Cowen	Kyle Boucher	PT Cut	Hold	$7→$6
May 6, 2026	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$6→$6
Feb 24, 2026	UBS	Lu Li	PT Cut	Neutral	$8→$6
Feb 24, 2026	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$7→$6
Nov 11, 2025	Piper Sandler	Dave Weiner	PT Cut	Overweight	$9→$9
Nov 5, 2025	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$6→$7
Nov 4, 2025	TD Cowen	Dan Brennan	PT Raise	Hold	$8→$9
Nov 4, 2025	UBS	Lu Li	PT Raise	Neutral	$6→$8
May 21, 2025	Scotiabank	Sung Ji Nam	Downgrade	Sector Outperform→Sector Perform	$20→$6
May 15, 2025	Piper Sandler	Dave Weiner	PT Cut	Overweight	$13→$9
May 8, 2025	Wells Fargo	Brandon Couillard	Downgrade	Overweight→Equal-Weight	$22→$6
May 7, 2025	Goldman Sachs	Matthew Sykes	PT Cut	Buy	$14→$8
May 7, 2025	UBS	Lu Li	PT Cut	Neutral	$16→$7
May 7, 2025	Raymond James	Andrew Cooper	PT Cut	Outperform	$19→$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6

UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.

Benzinga Newsdesk

PRO
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3

Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5 to $3.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3

Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5.5 to $3.

Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $4

TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $6 to $4.

Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $6

TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $7 to $6.

Benzinga Newsdesk